Table 2 Susceptibility of MRSA isolates to vancomycin and teicoplanin
From: Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004
| Â | Â | Â | Vancomycin MIC (%) | Teicoplanin MIC (%) | ||||
|---|---|---|---|---|---|---|---|---|
S/N | Year | # | ≤ 2 mg/L | 3 mg/L | 4 mg/L | ≤ 2 mg/L | 3 mg/L | 4 mg/L |
1 | 1999 | 336 | 199(59.2) | 120(35.7) | 17(5.1) | 225(70.0) | 99(29.5) | 12(3.5) |
2 | 2000 | 542 | 494(91.1) | 47(8.7) | 1(0.2) | 479(88.4) | 58(10.7) | 5(0.9) |
3 | 2001 | 533 | 385(72.2) | 133(25.0) | 15(2.8) | 293(55.0) | 160(30.0) | 80(15.0) |
4 | 2002 | 884 | 773(87.4) | 107(12.1) | 4(0.5) | 740(83.7) | 112(12.7) | 32(3.6) |
5 | 2003 | 785 | 653(83.2) | 132(16.8) | 0.00 | 623(79.4) | 162(20.6) | 0.00 |
6 | 2004 | 930 | 807(86.8) | 121(13.0) | 2(0.2) | 740(79.6) | 176(18.9) | 14(1.5) |
Total | 4010 | 3311(82.5) | 660(16.5) | 39 (1.0) | 3100 (77.3) | 767(19.1) | 143(3.6) | |